Search Bar & Filters
Found 15 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether calderasib combined with subcutaneous pembrolizumab can better treat non-small cell lung cancer NSCLC with the KRAS G12C mutation. The study compares this combination to pembrolizumab with chemotherapy to see if it helps patients live longer without their cancer growing or spreading. This is a phase 3 clinical trial assessing treatment effectiveness and safety in participants with advanced or metastatic nonsquamous NSCLC. Participants will be randomly assigned to one of two groups. One group receives pembrolizumab plus berahyaluronidase alfa as a subcutaneous injection every 6 weeks for up to 18 cycles about 2 years, along with calderasib tablets until treatment discontinuation. The other group receives pembrolizumab plus berahyaluronidase alfa with chemotherapy drugs pemetrexed and either carboplatin or cisplatin given intravenously on specified days in the first cycles, also until discontinuation criteria are met. During the study, participants will have regular assessments including tumor scans and health questionnaires to monitor progression free survival, overall survival, response rates, and quality of life. Adverse events and treatment tolerability will also be tracked up to approximately 81 months. The study aims to provide detailed information on the impact of these treatments on cancer progression and patient well-being over time.
Actively Recruiting
Researchers are evaluating new treatment options for people with locally advanced, unresected non-small cell lung cancer NSCLC that has a KRAS G12C gene mutation. This trial aims to learn if combining calderasib MK-1084 with durvalumab, an immunotherapy, after chemotherapy and radiation can help patients live longer without their cancer growing or spreading. Participants will be randomly assigned to receive either calderasib along with durvalumab or a placebo with durvalumab. Calderasib is taken as an oral tablet, while durvalumab is given by intravenous infusion. The study is blinded so neither participants nor researchers know who receives the active drug or placebo during treatment. During the study, participants will be monitored regularly to assess cancer progression, survival, quality of life, and side effects. This includes tumor testing, blood work, and questionnaires over up to approximately 6 years for progression-free survival and up to 9 years for overall survival and other health measures. The study is sponsored by Merck Sharp & Dohme LLC and follows participants from screening through long-term follow-up.
Actively Recruiting
Researchers are studying the long-term safety and tolerability of KarXT for treating mania or mania with mixed features in adults with Bipolar-I disorder. This phase 3 open-label extension trial focuses on participants who have either completed prior related studies or are newly diagnosed with specific criteria. The study aims to monitor adverse events and changes in symptoms over an extended period. Participants receive KarXT at specified doses, with some possibly receiving additional therapeutic doses of Lithium, Valproate, or Lamotrigine. The study does not involve placebo and is designed as a single-group intervention. The treatment and monitoring continue for up to 54 weeks, focusing on safety and symptom assessments. During the study, participants undergo regular evaluations including psychiatric assessments and safety monitoring. Researchers track treatment-emergent adverse events, serious adverse events, and changes in suicidal ideation using the Columbia-Suicide Severity Rating Scale. Additional assessments include rating scales for movement disorders and urinary symptoms. The total participation period extends up to about one year, with ongoing safety and tolerability evaluations.
Actively Recruiting
Researchers are studying the pharmacokinetics PK and safety of ublituximab given as a subcutaneous SC injection in people with relapsing multiple sclerosis MS. The study evaluates how the drug behaves in the body when injected at different sites and compares the bioavailability when administered by a prefilled pen versus a syringe. This Phase 2 trial is focused on treatment and aims to understand the best method of delivering ublituximab subcutaneously. Participants will receive ublituximab SC either at one of three different injection sites using a syringe or via a prefilled pen. The study randomly assigns participants to receive the drug using either the prefilled pen or the syringe. The treatment period includes assessments up to 12 weeks for primary PK measures and up to 120 weeks for safety and plasma concentration monitoring. During the study, participants will have blood samples taken to measure drug levels and safety will be monitored by tracking any adverse events. They will also report their satisfaction with the injection method through questionnaires up to week 96. The main outcome measured is the area under the curve AUC of ublituximab at steady state by week 12, with longer follow-up to assess plasma concentrations and side effects. The total study duration extends up to nearly three years, ensuring extended safety and treatment evaluation.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of adding KarXT to existing treatments for mania in adults with Bipolar-I Disorder. This trial focuses on participants experiencing an acute manic episode, with or without mixed features, who are already taking lithium, valproate, or lamotrigine. The study aims to improve mania symptoms, measured by changes in the Young Mania Rating Scale after five weeks. Participants will be randomly assigned to receive either KarXT in addition to their mood stabilizer or a placebo plus their mood stabilizer. The treatments are given in specified doses over the study period, with careful monitoring of side effects and other health measures. The study includes a double-blind design, meaning neither participants nor researchers know which treatment is given to ensure unbiased results. During the trial, participants will undergo regular assessments including psychiatric evaluations, rating scales for mania and other symptoms, and safety monitoring up to seven weeks. Researchers will track symptom changes, treatment responses, and any adverse events. Participants are involved in scheduled visits for evaluations and to maintain stable mood stabilizer doses. The total participation lasts until the primary outcome is measured at week five, with additional safety follow-up up to week seven.
Actively Recruiting
Researchers are conducting a Phase 3, randomized, double-blind, placebo-controlled study to evaluate KarXT in adults with Bipolar-I disorder experiencing acute manic or mixed episodes. The study focuses on assessing how well KarXT works compared to a placebo during a three-week inpatient treatment period. Participants must be hospitalized due to their acute symptoms, and the study includes a total duration of up to seven weeks covering screening, treatment, and safety follow-up. Participants are randomly assigned to receive either KarXT or a placebo with flexible dosing during the inpatient phase. The main goal is to observe changes in manic symptoms using the Young Mania Rating Scale over three weeks. The study monitors safety and efficacy through standardized psychiatric assessments and follows participants closely during the inpatient stay. During the trial, participants will undergo regular evaluations including psychiatric ratings and clinical global impressions to track symptom changes and treatment response. The study includes initial screening, a three-week double-blind treatment period while hospitalized, and a safety follow-up period to monitor participants health. The total participation time does not exceed seven weeks.
Actively Recruiting
Researchers are evaluating the safety, efficacy, and tolerability of sodium zirconium cyclosilicate SZC in children under 18 years old with hyperkalaemia, a condition involving high potassium levels. This phase 3, open-label study involves about 140 participants across roughly 46 sites in Europe, North America, and other locations. It starts with two age cohorts 6 to under 12 years and 12 to under 18 years, with potential expansion to younger cohorts based on data review by an independent monitoring committee. Treatment includes three phases the Correction Phase CP, Maintenance Phase MP, and Long-Term Maintenance Phase LTMP. Participants in CP receive SZC orally three times daily for up to 3 days until potassium levels normalize, with doses adjusted by body weight equivalent to adult doses of 5 g, 10 g, or 15 g. Those achieving normal potassium enter the MP, receiving once-daily SZC for 28 days with dose adjustments to maintain levels. Participants may then continue into the LTMP, following a similar dose regimen with monthly visits. Throughout the study, participants undergo blood tests, ECG monitoring, urine analyses, and safety assessments to track potassium levels, aldosterone, electrolytes, and kidney function. Researchers measure effectiveness by the ability to achieve and maintain normal potassium levels and monitor safety and tolerability in all phases. The study duration is about 28 weeks, including treatment and a safety follow-up one week after the last dose.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating an artificial intelligence AI software platform called Retina-AI to detect diabetic retinopathy DR, a complication of diabetes that affects the eyes. The study includes adults aged 18 to 90 who have diabetes mellitus or risk factors for developing diabetes. The goal is to assess the accuracy of this AI tool in identifying DR from eye images. During the study, participants will have fundus photos taken of their eyes using a non-mydriatic fundus camera, which does not require pupil dilation. Two images per eye are capturedone centered on the optic disc and one on the fovea. These images are then uploaded into the AI system, where a neural network processes them to detect signs of diabetic retinopathy. Participants will undergo imaging at the start of the study to provide baseline data. Researchers will measure the accuracy of the AI in detecting DR, including the percentage of invalid images and false positive results. The study is observational and involves no drug treatments. Participants data will be collected and analyzed to evaluate the AIs performance in screening for diabetic retinopathy.
Actively Recruiting
Researchers are studying inherited eye diseases, including both Mendelian and complex age-related conditions, in families from diverse nationalities and ethnic backgrounds. The study aims to identify the genes involved in inherited eye diseases such as cataracts, corneal dystrophies, retinal degenerations, myopia, and glaucoma, and to understand how these gene mutations cause disease. Participants and their families will undergo detailed eye exams and provide blood and saliva samples for genetic testing. The study includes linkage and association analyses, gene mutation screenings using methods like whole genome or exome sequencing, and biochemical characterization of gene products when needed. Blood samples may also be used for metabolic tests such as hemoglobin A1c and glucose tolerance. Participants will have one visit lasting 3 to 4 hours that includes medical and family history review, eye exam with pupil dilation, electroretinography, blood tests, and saliva sample collection. Researchers will discuss genetic test results with participants. The main outcome is documenting the clinical and genetic features of inherited visual disorders, with monitoring continuing until 2032.
Actively Recruiting
Researchers are evaluating the efficacy and safety of cariprazine in treating schizophrenia among adolescents aged 13 to 17 years. This international, multicenter study is designed as a randomized, double-blind, placebo-controlled trial to understand how cariprazine affects symptoms of schizophrenia in this younger population. Participants will be randomly assigned to receive either cariprazine capsules at doses of 1.5 mg or 4.5 mg once daily, or matching placebo capsules once daily. The treatment phase lasts for six weeks, during which participants take the assigned capsules orally every day. During the study, participants will be monitored regularly to assess changes in their schizophrenia symptoms using the Positive and Negative Syndrome Scale PANSS. Researchers will also evaluate safety and tolerability throughout the trial. The main measurement is the change in PANSS total score from the start to the end of the six-week period. The study is designed to last until December 2026.
1-10 of 15
1